Individual research compounds explained step by step - what the molecule is, what study contexts it appears in, and how researchers frame it.
33 articles tagged “Compound Profiles”
A research-first breakdown of the body protection compound - what BPC-157 is, the preclinical-only evidence base, the peptide-vs-steroid question, why recovery and hormonal claims overreach, and why purity and COAs matter.
The GHRH analogue mechanism, the narrow approved visceral-fat indication, how tesamorelin differs from recovery peptides, and where general fat-loss and longevity claims go too far.
How TB-500 relates to (but differs from) Thymosin Beta-4, what the preclinical tissue-repair and cell-migration literature actually studies, the human-trial gap, and why it is prohibited in tested sport.
PT-141 is an FDA-approved melanocortin-4 receptor agonist for hypoactive sexual desire disorder. How it works, clinical evidence from the DESIRE trials, nasal spray vs injection, comparison to Viagra/Cialis, dosage, side effects, and why the mechanism differs from phosphodiesterase inhibitors.
The FDA's Pharmacy Compounding Advisory Committee reviews BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon on July 23-24, 2026 for potential 503A Bulks List inclusion. What the meeting means for research, regulation and accessibility - and why a compounding review is not an FDA approval.
BPC-157 and TB-500 are scheduled for FDA advisory committee discussion on July 23, 2026 (evaluated uses: ulcerative colitis and wound healing). What it means for regenerative peptide research, compounding policy and research-use standards - and why a review is not an approval.
On July 24, 2026 the FDA's compounding advisory committee discusses Semax, Epitalon and Emideltide (DSIP). What it could mean for neuro-longevity peptide research and compounding regulation - and why a review is not an approval or a clinical endorsement.
No - BPC-157 is not an FDA-approved drug. It has never completed a New Drug Application and is supplied as a research-use-only compound. The 2026 status, including the July 2026 503A compounding review, and why a review is not an approval.
Not in the way the word suggests. BPC-157 is a research-use-only compound; the FDA's 2023 review kept it off the 503A Bulks List for human-use compounding, it returns for discussion in July 2026, and WADA prohibits it in sport. The nuance behind "banned", explained.
KPV - the anti-inflammatory tripeptide (lysine-proline-valine) derived from alpha-MSH - is on the FDA's July 23, 2026 compounding agenda (evaluated uses: wound healing and inflammatory conditions). What KPV is, the research context, and why a review is not an approval.
No - TB-500 is not an FDA-approved drug. It is a research-use-only peptide related to thymosin beta-4. The 2026 status, the July 2026 503A compounding review, the WADA sport ban, and why a review is not an approval.
No - Semax is not FDA approved in the US (though it is a registered medicine in Russia). It is supplied as a research-use-only compound. The 2026 status, the July 2026 503A review, and why a review is not an approval.
No - Epitalon (also spelled Epithalon) is not an FDA-approved drug; it is a research-use-only compound studied in longevity research. The 2026 status, the July 2026 503A review, and why a review is not an approval.
In April 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would end large-scale compounding of these GLP-1 drugs. The proposal, the June 2026 comment deadline, and how it differs from the research-compound space.
How peptides went from FDA Category 2 prohibition in 2023 to a fresh 503A review in 2026 - the April 2026 Federal Register notice, the 12 peptides under review, the compounder lawsuits, the HHS policy push, and what the July 2026 PCAC meeting will decide.
A 2026 review in Frontiers in Aging maps nine therapeutic peptides onto the hallmarks of aging - from tirzepatide and Epitalon to GHK-Cu, BPC-157, TB-500, Semax, CJC-1295/Ipamorelin and PT-141 - separating FDA-approved agents from investigational compounds.
How peptides intersect with stem-cell and regenerative-medicine research - as signalling molecules, as self-assembling hydrogel scaffolds for 3D cell culture, and as growth factors such as IGF-1. What the peer-reviewed literature describes vs the longevity-clinic claims. Research use only.
Des(1-3) IGF-1 vs Long R3 IGF-1 compared - structure, IGF-binding-protein affinity, half-life and potency, the recombinant-protein research context, and the WADA/USADA prohibited status with health-risk warnings. Research use only; not for human use.
Ipamorelin is a selective ghrelin-receptor (GHSR) agonist; sermorelin is a GHRH analogue acting upstream on the pituitary. Mechanism, GH-release shape, side-effect comparison, and why the two are co-studied as a complementary pair. Research use only.
Both are ghrelin-receptor (GHSR) agonists, but hexarelin is the more potent GH releaser with CD36 cardiac activity, while ipamorelin is the cleaner, selective option with slower desensitisation. Mechanism, side effects and desensitisation compared. Research use only.
Both prompt the pituitary through the GHRH receptor, but tesamorelin is a stabilised, more potent molecule with dedicated visceral-fat research, while sermorelin is the shorter GHRH 1-29 fragment. Mechanism, potency and half-life compared. Research use only.
A 39-amino-acid dual agonist developed by Eli Lilly, approved as Mounjaro and Zepbound. Mechanism, half-life, the SURPASS and SURMOUNT trial data, the SURMOUNT-5 head-to-head against semaglutide, and the GLP-1 RC-T research-compound posture.
The 31-amino-acid peptide behind Ozempic, Wegovy and Rybelsus. Mechanism, half-life, the STEP / SUSTAIN / SELECT evidence base, oral vs injectable formulation, and the GLP-1 RC-S research-compound posture.
Eli Lilly’s investigational triple agonist (LY3437943). Mechanism, the ~24% Phase 2 weight-reduction headline, the TRIUMPH Phase 3 programme, and the GLP-1 RC-R research-compound posture. Pairs with the UK sourcing guide.
The 15-amino-acid pentadecapeptide derived from a body protective compound first isolated in human gastric juice. Mechanism (angiogenesis, NO modulation, fibroblast migration), the pre-clinical evidence base, the human-trial gap, and the “Wolverine stack” framing with TB-500.
The only FDA-approved peptide for visceral fat reduction. A 44-amino-acid GHRH analogue with a trans-3-hexenoic acid N-terminal modification - mechanism, the NEJM Phase 3 visceral-adipose-tissue data, and how it differs mechanistically from CJC-1295 and sermorelin.
The most-studied GHRH + GHRP research combination. CJC-1295 with DAC vs no-DAC explained, ipamorelin’s selective ghrelin-receptor mechanism, why the pairing has mechanistic logic rather than just marketing logic, and how the pair compares to tesamorelin and sermorelin.
A neutral research-side map of the peptides that come up in bodybuilding discussion - GH-axis stack, healing pair (BPC-157 + TB-500), GLP-1 cluster for cuts. WADA framing throughout.
Golf injuries are asymmetric, rotational and chronic. Why TB-500 keeps coming up in tour-locker-room conversation - mechanism, the human-trial gap, and the WADA listing every competitor needs to know.
A tattoo is, biologically, a controlled dermal injury. The four wound-healing phases, BPC-157’s animal-study mechanisms (angiogenesis, collagen organisation, fibroblast migration) and where the "Wolverine stack" with TB-500 fits in.
Why labs care about this tiny copper-bound peptide: skin matrix, gene-expression studies and wound models - explained step by step for non-specialists.
A short signal from the cell’s energy factories - how researchers link it to exercise, metabolism and ageing models, without hype.
Two heavily studied metabolic peptides side by side: how they are alike, how they differ, and what papers usually measure - without treating either as a consumer product.
Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.